Search Results | Cancer Research | American Association for Cancer Research

1-20 of 44

2 3

Sort by

Sort Order Select

Journal Articles

Abstract 605: MoA-based potency bioassays for immunotherapy programs targeting the TIGIT/CD112R/CD226 axis

Jamison Grailer, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong, Zhi-Jie Jey Cheng

Cancer Res (2022) 82 (12_Supplement): 605.

DOI: https://doi.org/10.1158/1538-7445.AM2022-605

Published: 15 June 2022

View article

Journal Articles

Abstract 2750: Bioluminescent bioassays for the discovery and development of molecular and cellular T-cell redirecting cancer therapy

Julia Gilden, Jamison Grailer, Michael Slater, Pete Stecha, Jim Hartnett, Dan Lazar, Gopal Krishnan, Frank Fan, Mei Cong, Zhijie Jey Cheng

Cancer Res (2022) 82 (12_Supplement): 2750.

DOI: https://doi.org/10.1158/1538-7445.AM2022-2750

Published: 15 June 2022

View article

Journal Articles

Abstract 4249: Quantitative PBMC ADCC bioassay and ADCC reporter bioassays for immunotherapy and SARS-CoV-2 monoclonal antibody development

Pete Stecha, Jun Wang, Denise Garvin, Julia Gilden, Jamison Grailer, Jim Hartnett, Frank Fan, Mei Cong, Zhi-jie Jey Cheng

Cancer Res (2022) 82 (12_Supplement): 4249.

DOI: https://doi.org/10.1158/1538-7445.AM2022-4249

Published: 15 June 2022

View article

Journal Articles

Abstract 1875: Novel cell-based bioassays for monoclonal antibody and bispecific molecules in PD-1 blockade monotherapy and combination therapy

Jamison Grailer, Julia Gilden, Jun Wang, Denise Garvin, Pete Stecha, Jim Hartnett, Steven Edenson, Frank Fan, Mei Cong, Zhi-jie Jey Cheng

Cancer Res (2022) 82 (12_Supplement): 1875.

DOI: https://doi.org/10.1158/1538-7445.AM2022-1875

Published: 15 June 2022

View article

Journal Articles

Abstract 506: A homogenous PBMC ADCC bioassay enables bridging studies with ADCC reporter bioassays in immunotherapy monoclonal antibody development

Pete Stecha, Denise Garvin, Julia Gilden, Jun Wang, Jamison Grailer, Jim Hartnett, Gopal B. Krishnan, Frank Fan, Mei Cong, Zhijie Jey Cheng

Cancer Res (2021) 81 (13_Supplement): 506.

DOI: https://doi.org/10.1158/1538-7445.AM2021-506

Published: 01 July 2021

View article

Journal Articles

Abstract 334: Novel bioluminescent bioassays for the discovery and development of molecular and cellular T cell-redirecting cancer therapy

Julia Gilden, Jamison Grailer, Michael Slater, Pete Stecha, Jim Hartnett, Dan Lazar, Vanessa Ott, Frank Fan, Mei Cong, Zhijie Jey Cheng

Cancer Res (2021) 81 (13_Supplement): 334.

DOI: https://doi.org/10.1158/1538-7445.AM2021-334

Published: 01 July 2021

View article

Journal Articles

Abstract 1650: MoA-based reporter bioassays enable quantitative potency determination for therapeutic biologics targeting co-stimulatory and co-inhibitory immune checkpoint receptors

Jamison Grailer, Julia Gilden, Pete Stecha, Denise Garvin, Jun Wang, michael Beck, Jim Hartnett, Frank Fan, mei cong, Zhi-Jie Jey Cheng

Cancer Res (2021) 81 (13_Supplement): 1650.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1650

Published: 01 July 2021

View article

Journal Articles

Abstract 1645: Cell-based reporter bioassays for the development of Fc-functional and Fc-silent SIRPα/CD47 checkpoint inhibitors

Jonathan Mitchell, Jamison Grailer, Jim Hartnett, Frank Fan, Mei Cong, Zhijie Jey Cheng

Cancer Res (2021) 81 (13_Supplement): 1645.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1645

Published: 01 July 2021

View article

Journal Articles

Abstract 1729: Reproducible, MoA-reflecting reporter-based bioassays to enable drug development of biosimilars and biobetters

Rich Moravec, Dun Li, Jennifer Wilkinson, Brad Swanson, Frank Fan, Mei Cong

Cancer Res (2021) 81 (13_Supplement): 1729.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1729

Published: 01 July 2021

View article

Journal Articles

Abstract 3163: Cell-based reporter bioassays for development of Fc-functional and Fc-silent SIRPa/CD47 checkpoint inhibitors

Jonathan Mitchell, Jamison Grailer, Jim Hartnett, Frank Fan, Mei Cong, Zhijie Jey Cheng

Cancer Res (2020) 80 (16_Supplement): 3163.

DOI: https://doi.org/10.1158/1538-7445.AM2020-3163

Published: 15 August 2020

View article

Journal Articles

Abstract 944: Quantitative cell-based reporter bioassays for functional characterization of immunotherapeutic biologics targeting co-stimulatory and co-inhibitory immune checkpoint receptors

Jamison Grailer, Julia Gilden, Pete Stecha, Denise Garvin, Jun Wang, Michael Beck, Jim Hartnett, Gopal Krishnan, Frank Fan, Mei Cong, Zhi-jie Jey Cheng

Cancer Res (2020) 80 (16_Supplement): 944.

DOI: https://doi.org/10.1158/1538-7445.AM2020-944

Published: 15 August 2020

View article

Journal Articles

Abstract 5251: Reproducible, MoA-reflecting reporter-based bioassays to enable drug development of biosimilars and biobetters

Steven Edenson, Richard Moravec, Dun Li, Jennifer Wilkinson, Frank Fan, Mei Cong

Cancer Res (2020) 80 (16_Supplement): 5251.

DOI: https://doi.org/10.1158/1538-7445.AM2020-5251

Published: 15 August 2020

View article

Journal Articles

Abstract 5658: A homogenous PBMC ADCC bioassay enables bridging studies with ADCC reporter bioassays in immunotherapy monoclonal antibody development

Pete Stecha, Denise Garvin, Julia Gilden, Jun Wang, Jamison Grailer, Jim Hartnett, Vanessa Ott, Frank Fan, Mei Cong, Zhijie Jey Cheng

Cancer Res (2020) 80 (16_Supplement): 5658.

DOI: https://doi.org/10.1158/1538-7445.AM2020-5658

Published: 15 August 2020

View article

Journal Articles

Abstract 5808: Examination of clinically relevant inhibitor selectivity in live cells across the CDK family

James Vasta, Carrow Wells, Cesear Corona, Jennifer Wilkinson, Chad Zimprich, Morgan Ingold, Domenic Ogno, Marie Schwinn, Thomas Machleidt, Mei Cong, Frank Fan, Kristin Huwiler, Amy Landreman, Julie E. Pickett, Kilian Huber, Matthew Robers

Cancer Res (2020) 80 (16_Supplement): 5808.

DOI: https://doi.org/10.1158/1538-7445.AM2020-5808

Published: 15 August 2020

View article

Journal Articles

Abstract 6407: A live cell method to assess E3 ligase and target protein occupancy for PROTACs

James Vasta, Cesear Corona, Jennifer Wilkinson, Morgan R. Ingold, Chad Zimprich, Marie Schwinn, Thomas Machleidt, Jim Hartnett, Mei Cong, Frank Fan, Richard L. Somberg, Matthew Robers

Cancer Res (2020) 80 (16_Supplement): 6407.

DOI: https://doi.org/10.1158/1538-7445.AM2020-6407

Published: 15 August 2020

View article

Journal Articles

Abstract 2179: Novel bioluminescent bioassays for the discovery and development of molecular and cellular T cell redirecting cancer therapy

Julia K. Gilden, Jamison Grailer, Michael Slater, Pete Stecha, Jim Hartnett, Dan Lazar, Frank Fan, Mei Cong, Zhijie Jey Cheng

Cancer Res (2020) 80 (16_Supplement): 2179.

DOI: https://doi.org/10.1158/1538-7445.AM2020-2179

Published: 15 August 2020

View article

Journal Articles

Abstract 1215: Improved T cell activation bioassays for development of bispecific antibodies and engineered T cell immunotherapies

Pete Stecha, Denise Garvin, Jim Hartnett, Brad Swanson, Frank Fan, Mei Cong, Zhi-jie Jey Cheng

Cancer Res (2019) 79 (13_Supplement): 1215.

DOI: https://doi.org/10.1158/1538-7445.AM2019-1215

Published: 01 July 2019

View article

Journal Articles

Abstract 2393: Bridging MOA-based reporter bioassays with PBMC based ADCC for immunotherapy drug development

Mei Cong, Pete Stecha, Aileen paguio, brock binkowski, Zhi-Jie Cheng, Frank Fan

Cancer Res (2019) 79 (13_Supplement): 2393.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2393

Published: 01 July 2019

View article

Journal Articles

Abstract 3053: Development of novel cell-based bioassays for the development of biologics targeting LAG-3 and PD-1xLAG-3

Jamison Grailer, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong, Zhi-jie Jey Cheng

Cancer Res (2019) 79 (13_Supplement): 3053.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3053

Published: 01 July 2019

View article

Journal Articles

Abstract 3181: A novel, bioluminescent assay for the selective detection of target cell killing in mixed cultures

Brock Binkowski, Aileen Paguio, Christopher Eggers, Braeden Butler, Michael Beck, Frank Fan

Cancer Res (2019) 79 (13_Supplement): 3181.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3181

Published: 01 July 2019

View article

2 3

NARROW

Abstract 605: MoA-based potency bioassays for immunotherapy programs targeting the TIGIT/CD112R/CD226 axis

Abstract 2750: Bioluminescent bioassays for the discovery and development of molecular and cellular T-cell redirecting cancer therapy

Abstract 4249: Quantitative PBMC ADCC bioassay and ADCC reporter bioassays for immunotherapy and SARS-CoV-2 monoclonal antibody development

Abstract 1875: Novel cell-based bioassays for monoclonal antibody and bispecific molecules in PD-1 blockade monotherapy and combination therapy

Abstract 506: A homogenous PBMC ADCC bioassay enables bridging studies with ADCC reporter bioassays in immunotherapy monoclonal antibody development

Abstract 334: Novel bioluminescent bioassays for the discovery and development of molecular and cellular T cell-redirecting cancer therapy

Abstract 1650: MoA-based reporter bioassays enable quantitative potency determination for therapeutic biologics targeting co-stimulatory and co-inhibitory immune checkpoint receptors

Abstract 1645: Cell-based reporter bioassays for the development of Fc-functional and Fc-silent SIRPα/CD47 checkpoint inhibitors

Abstract 1729: Reproducible, MoA-reflecting reporter-based bioassays to enable drug development of biosimilars and biobetters

Abstract 3163: Cell-based reporter bioassays for development of Fc-functional and Fc-silent SIRPa/CD47 checkpoint inhibitors

Abstract 944: Quantitative cell-based reporter bioassays for functional characterization of immunotherapeutic biologics targeting co-stimulatory and co-inhibitory immune checkpoint receptors

Abstract 5251: Reproducible, MoA-reflecting reporter-based bioassays to enable drug development of biosimilars and biobetters

Abstract 5658: A homogenous PBMC ADCC bioassay enables bridging studies with ADCC reporter bioassays in immunotherapy monoclonal antibody development

Abstract 5808: Examination of clinically relevant inhibitor selectivity in live cells across the CDK family

Abstract 6407: A live cell method to assess E3 ligase and target protein occupancy for PROTACs

Abstract 2179: Novel bioluminescent bioassays for the discovery and development of molecular and cellular T cell redirecting cancer therapy

Abstract 1215: Improved T cell activation bioassays for development of bispecific antibodies and engineered T cell immunotherapies

Abstract 2393: Bridging MOA-based reporter bioassays with PBMC based ADCC for immunotherapy drug development

Abstract 3053: Development of novel cell-based bioassays for the development of biologics targeting LAG-3 and PD-1xLAG-3

Abstract 3181: A novel, bioluminescent assay for the selective detection of target cell killing in mixed cultures

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only